Rocuronium bromide is one of the commonly used neuromuscular blocking agent. Rocuronium is eliminated primarily by the liver and slightly by the kidneys. Its duration of action is not significantly affected by renal disease. However, previous studies of rocuronium in patients with end-stage renal disease have not consistently demonstrated an effect of end-stage renal disease on the pharmacokinetics and pharmocodynamics of rocuronium.
Khuenl-Brady et al. [1] found that the duration and recovery index of rocuronium did not differ between patients with chronic renal failure and normal renal function under isoflurane anesthesia even when the drug was given in repeated doses for maintenance. They concluded that rocuronium appeared to be suitable for patients with chronic renal failure. Cooper et al. [2] demonstrated that the differences in onset time, duration of clinical relaxation, recovery index, and the time for train-of-four (TOF) ratio to return spontaneously to 0.7 were not significant between patients with and without renal failure during anesthesia with nitrous oxide, fentanyl and isoflurane.
However the differences in the rates of clearance and the mean residence times were significant between patients with and without renal failure. They concluded that the effects of rocuronium may be prolonged in patients with renal disease, because of a decreased clearance of the drug.
The clinical duration and the time to recovery of the TOF to 70% of a bolus dose of 0.6 mg/kg rocuronium were prolonged significantly in patients with renal failure compared to healthy control under propofol anesthesia. Clearance of rocuronium was reduced by 39% in the renal failure patients compared to control, with an 84% increase in the mean residence time [3] . Szenohradszky et al. [4] found no difference in total plasma clearance between control and renal transplant patients under isoflurane anesthesia, whereas volume of distribution was greater in renal transplant patients than in control patients. This 
